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Abstract
Vascular endothelial growth factor receptor-3 (VEGFR3) signalling
promotes lymphangiogenesis. While there are many reported
mechanisms of VEGFR3 activation, there is little understanding of
how VEGFR3 signalling is attenuated to prevent lymphatic vascular
overgrowth and ensure proper lymph vessel development. Here,
we show that endothelial cell-specific depletion of integrin-linked
kinase (ILK) in mouse embryos hyper-activates VEGFR3 signalling
and leads to overgrowth of the jugular lymph sacs/primordial thor-
acic ducts, oedema and embryonic lethality. Lymphatic endothelial
cell (LEC)-specific deletion of Ilk in adult mice initiates lymphatic
vascular expansion in different organs, including cornea, skin and
myocardium. Knockdown of ILK in human LECs triggers VEGFR3
tyrosine phosphorylation and proliferation. ILK is further found to
impede interactions between VEGFR3 and b1 integrin in vitro and
in vivo, and endothelial cell-specific deletion of an Itgb1 allele
rescues the excessive lymphatic vascular growth observed upon
ILK depletion. Finally, mechanical stimulation disrupts the assem-
bly of ILK and b1 integrin, releasing the integrin to enable its inter-
action with VEGFR3. Our data suggest that ILK facilitates
mechanically regulated VEGFR3 signalling via controlling its inter-
action with b1 integrin and thus ensures proper development of
lymphatic vessels.
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Introduction
The importance of the lymphatic vasculature is demonstrated by its
numerous physiological functions, including maintenance of fluid
homeostasis, facilitation of immune response and uptake of lipids
and vitamins. Moreover, it is involved in pathological conditions
such as primary and secondary lymphoedema, obesity develop-
ment, tumour cell dissemination and growth, reverse cholesterol
transport, hypertension, glaucoma, inflammation and regeneration
or damage after myocardial infarction (Karkkainen et al, 2000;
Skobe et al, 2001; Harvey et al, 2005; Wilting et al, 2009; Martel
et al, 2013; Thomson et al, 2014; Huang et al, 2015; Klotz et al,
2015; Escobedo et al, 2016; Gousopoulos et al, 2016; Lund et al,
2016; Tatin et al, 2017; Zhang et al, 2018). Growth of lymphatic
vessels, known as lymphangiogenesis, is critically regulated by
vascular endothelial growth factor receptor-3 (VEGFR3) signalling,
also required for normal blood vascular development (Dumont et al,
1998; Veikkola et al, 2001). However, after blood vessel formation
is completed, VEGFR3 expression shifts to lymphatic endothelial
cells (LECs), where it is strictly required for the development of the
lymphatic vascular system and lymphangiogenesis (Kaipainen et al,
1995; Kukk et al, 1996; Karkkainen et al, 2004). After birth,
VEGFR3 is mainly expressed in LECs, but can also be found in
vascular endothelial cells during sprouting angiogenesis and in
some fenestrated endothelia (Kaipainen et al, 1995; Partanen et al,
2000; Tammela et al, 2008).
VEGFR3 belongs to the family of receptor tyrosine kinases
(RTKs), and its signalling can be activated by binding of vascular
endothelial growth factor (VEGF)-C or VEGF-D (Joukov et al, 1996;
Jeltsch et al, 1997; Achen et al, 1998). In addition, different co-
receptors of VEGFR3 have been reported (Yuan et al, 2002; Dixelius
et al, 2003; Alam et al, 2004; Favier et al, 2006; Nilsson et al, 2010;
Wang et al, 2010; Xu et al, 2010). Binding of ligands to the extra-
cellular part of the receptor induces its dimerisation and
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autophosphorylation. The latter induces recruitment of intracellular
proteins and downstream activation of signalling pathways leading
to cell survival, migration and proliferation (Makinen et al, 2001;
Salameh et al, 2005).
A novel aspect of lymphatic vascular biology is the role of inte-
grins and mechanical forces in VEGFR3 signalling, lymphatic vascu-
lar growth and valve morphogenesis (Wang et al, 2001; Bazigou
et al, 2009; Galvagni et al, 2010; Planas-Paz et al, 2012; Baeyens
et al, 2015; Sweet et al, 2015; Sabine et al, 2016; Choi et al, 2017b).
Integrins are transmembrane receptors, which bind to extracellular
matrix (ECM) components, and are essential for “outside-in” and
“inside-out” signalling of the cell, thereby transducing mechanical
stimulations. At least 24 unique heterodimers composed of a and b
subunits are known today (Hynes, 2002; Humphries et al, 2006).
However, predominantly b1 integrins have been reported to be
involved in lymphatic vascular development and lymphangiogenesis
(Huang et al, 2000; Okazaki et al, 2009; Garmy-Susini et al, 2010;
Planas-Paz et al, 2012). After binding to the ECM, b1 integrin (e.g.
as a subunit of the a5b1 integrin, a receptor for fibronectin) interacts
with VEGFR3 to induce c-src-dependent VEGFR3 tyrosine phospho-
rylation (Wang et al, 2001; Zhang et al, 2005; Galvagni et al, 2010).
Further, both the fluid flow through a lymphatic vessel and the
interstitial fluid pressure mechanically stimulate LECs (as they are
attached to the surrounding ECM via integrins or anchoring fila-
ments); these stimuli trigger VEGFR3 phosphorylation and LEC
proliferation (Planas-Paz et al, 2012; Planas-Paz & Lammert, 2014;
Baeyens et al, 2015; Sabine et al, 2016; Urner et al, 2018). Notably,
this mechanoinduced VEGFR3 signalling strictly depends on b1 inte-
grin (Planas-Paz et al, 2012).
To our knowledge, no study has reported the role of integrin-
linked kinase (ILK) in VEGFR3 signalling or lymphatic vascular
development. ILK is a cytoplasmic protein known to—directly or
indirectly—interact with b1 and b3 integrins (Hannigan et al,
1996; Li et al, 1999; Pasquet et al, 2002), and it has been identi-
fied as a kinase (Hannigan et al, 1996). However, since mice
harbouring mutations within the proposed autophosphorylation
site of ILK are viable and phenotypically normal (Lange et al,
2009), its most vital function may be to serve as an adaptor
protein modulating cell-matrix interactions and downstream signal-
ling (Ghatak et al, 2013). ILK is also found as a central component
of the ILK/PINCH/parvin (IPP) complex to ensure linkage between
integrins and the actin cytoskeleton (Tu et al, 2001; Zervas et al,
2001; Sakai et al, 2003; Vaynberg et al, 2018); it either inhibits or
increases cell proliferation depending on the tissue (Gkretsi et al,
2008; Serrano et al, 2013).
In this study, we investigated the specific role of ILK in
VEGFR3 signalling of LECs. We found that ILK acts as a cell-
autonomous inhibitor of VEGFR3 signalling during embryonic
development as well as in the adult. Specifically, deletion of Ilk in
LECs resulted in increased VEGFR3 phosphorylation and cell
proliferation, as well as lymphatic vascular overgrowth in the
mouse embryo. Further, we identified ILK as a regulator of lymph
vessel expansion in the heart after myocardial infarction as well as
in the skin and cornea of adult mice. Mechanistically, we observed
increased interaction of VEGFR3 and b1 integrin in the absence of
ILK, and genetic rescue experiments showed that ILK regulates
VEGFR3 signalling and lymph vessel growth by controlling b1
integrin. Finally, we found that mechanical stimulation of LECs
disrupts the complex of ILK and b1 integrin, reduces expression of
a-parvin and enables b1 integrin to better interact with VEGFR3.
Our data indicate that ILK facilitates mechanosensitive VEGFR3
signalling and physiologic lymph vessel expansion by controlling
b1 integrin-mediated VEGFR3 activation.
Results
ILK is required to control LEC proliferation and prevent lymphatic
vascular overgrowth during mouse embryonic development
In order to investigate the role of ILK in lymphatic vascular devel-
opment, we used Flk1-Cre mice to delete Ilk in the endothelium of
mouse embryos (Sakai et al, 2003; Licht et al, 2004). In contrast to
embryos with heterozygous endothelial cell-specific Ilk deletion (re-
ferred to as “control”), mouse embryos with homozygous Ilk dele-
tion (referred to as “ILK K.O.”) died from E13.5 onwards
(Appendix Fig S1A). In comparison with control embryos (Fig 1A–
D), ILK K.O. embryos were characterised by dorsolateral oedema
and head bleeding (Fig 1E). We first analysed the jugular lymph
sacs (jls), also called the primordial thoracic ducts (pTD), using
lymphatic vessel endothelial hyaluronan receptor-1 (Lyve1) and
CD31 staining. The jls/pTDs are the first lymphatic structures form-
ing pairwise in the developing embryo and give rise to the majority
of the entire lymphatic vascular network (Wigle & Oliver, 1999;
Wigle et al, 2002; Srinivasan et al, 2007; Yang et al, 2012; Hager-
ling et al, 2013). Notably, we observed a profound expansion of the
jls/pTD in ILK K.O. embryos compared to control embryos, visible
from E13.0 onwards (Fig 1B–D and F–H). At E14.5, the dermal
lymphatic vessels in ILK K.O. embryos were also increased in size,
and we observed both lymphatic and blood vascular sprouting
defects (Appendix Fig S2A–G).
We next quantified the number of LECs (stained for Lyve1 or
Prox1 as lymphatic endothelial markers) and their proliferation
within the jls/pTD (Fig 1I–L) to determine whether it coincides
with the increased size of the jls/pTD. Indeed, the total LEC
number of the jls/pTD was significantly increased in ILK K.O.
embryos at E13.5 compared to control littermates (Fig 1M and
Appendix Fig S3A–F). Consistent with the increased size of the
jls/pTD and greater number of LECs, LEC proliferation in ILK K.O.
embryos was found to be significantly increased from E13.0
onwards with both phospho-Histone H3 and Ki67 used as markers
for proliferation (Figs 1N and EV1A–I and Appendix Fig S4A–I). In
contrast, proliferation of blood endothelial cells (BECs) that were
previously shown to be affected by Ilk deletion (Friedrich et al,
2004; Malan et al, 2013) was unchanged in the jugular regions
of E13.5 ILK K.O. embryos compared to controls (Appendix Fig
S5A–O).
To analyse whether ILK is involved in regulating lymphatic
vascular growth and LEC proliferation along with other IPP
complex members, we deleted Parva, the gene for a-parvin, in
endothelial cells (referred to as “a-parvin K.O.”) (Fraccaroli et al,
2015). Both a- and b-parvin were shown to link ILK to the F-actin
cytoskeleton (Nikolopoulos & Turner, 2000; Olski et al, 2001). In
a-parvin K.O. embryos, a higher number of LECs (Fig EV2A–C)
and more LEC proliferation (Fig EV2D–F) were observed compared
to control littermates, confirming a regulatory role of the IPP
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complex. Finally, we confirmed that the observed effects on LEC
proliferation in ILK K.O. embryos are derived from the role of ILK
specifically in LECs by restricting Ilk deletion to LECs (and LEC
progenitors), but not BECs, using the Prox1-CreERT2 promoter (re-
ferred to as “induced ILK K.O.”, Appendix Fig S1B; Bazigou et al,
2011). Consistently, we observed increased LEC proliferation in
the jls/pTD of E13.5 induced ILK K.O. embryos compared to
controls (Fig EV3A–J).
These results show that ILK, as a member of the IPP complex, is
strictly required in LECs to inhibit excessive LEC proliferation and
hyperplasia of the lymphatic vasculature during early embryonic
development.
ILK controls VEGFR3 signalling during mouse
embryonic development
We next analysed Ilk gene expression in LECs during different devel-
opmental stages of wild-type embryos (referred to as “control”,
Appendix Fig S6A) along with LEC proliferation (Appendix Fig S6B)
and VEGFR3 tyrosine phosphorylation (Appendix Fig S6C). Analysis
of mRNA levels suggests an opposite Ilk expression pattern
compared to both LEC proliferation and VEGFR3 phosphorylation,
consistent with the hypothesis that ILK is a negative regulator of LEC
proliferation and VEGFR3 activity. Further, the ILK protein could be
detected in LECs sorted from mouse embryos at the E13.5 embryonic
stage when LEC proliferation and VEGFR3 activation are low
compared to earlier embryonic stages (Appendix Fig S6D). We
subsequently analysed VEGFR3 signalling in LECs of E13.5 ILK K.O.
embryos versus E13.5 control embryos by proximity ligation assays
(PLA), in which antibodies against VEGFR3 and phospho-tyrosine
were used (Fig 2A–D). Since both VEGFR3 and VEGFR2 are
expressed in LECs of the E13.5 jls/pTD (Appendix Fig S7A–H), we
also performed a PLA for VEGFR2/p-Tyr (Fig 2E–H). Notably, the
average number of VEGFR3/phospho-tyrosine (VEGFR3/p-Tyr) PLA
dots was doubled in LECs within the jls/pTD region of E13.5 ILK
K.O. embryos compared to controls (Fig 2I), while the PLA for
VEGFR2/p-Tyr revealed no significant difference between ILK K.O.
and control embryos (Fig 2J and K). Focussing on VEGFR3, we also
analysed its activity in Parva-deficient embryos, and found VEGFR3
tyrosine phosphorylation to be higher in a-parvin K.O. embryos than
in control littermates (Appendix Fig S8A–E), but to a lesser extent
than in ILK K.O. embryos (Fig 2I). Finally, we confirmed that also
significantly more VEGFR3 activation was observed in induced ILK
K.O. embryos, when Ilk was deleted from LECs using the Prox1
promoter (Fig EV4A–E). Thus, our data indicate that ILK inhibits
VEGFR3, but not VEGFR2, signalling in LECs during embryonic
development.
ILK is required to prevent VEGFR3 and b1 integrin interaction in
LECs during mouse embryonic development
VEGFR3 tyrosine phosphorylation can be induced by binding of b1
integrin to the ECM (Wang et al, 2001; Galvagni et al, 2010). Simi-
larly, VEGFR3 is phosphorylated in a b1 integrin-dependent manner
upon mechanical stimulation of endothelial cells (Planas-Paz et al,
2012; Lorenz et al, 2018). As ILK interacts—directly or indirectly—
with the intracellular domain of b1 integrin (Hannigan et al, 1996;
Montanez et al, 2008), we first investigated whether either its
expression or activation was changed upon ILK depletion in LECs.
Integrin activation is associated with conformational changes in the
heterodimer that allow interaction and clustering with intracellular
signalling molecules, thereby initiating integrin-mediated signalling
(reviewed in Avraamides et al, 2008). We used antibodies against
total and activated b1 integrin on embryonic sections to detect its
expression and activity in LECs of the jls/pTD (Appendix Fig S9A–
H). However, no major difference in the staining intensity of either
total or activated b1 integrin in the LECs of ILK K.O. embryos versus
controls was observed at E13.5 (Appendix Fig S9I and J), when
VEGFR3 phosphorylation and LEC proliferation differed between
these embryos.
Next, since VEGFR3 phosphorylation involves physical interac-
tion between VEGFR3 and b1 integrin (Wang et al, 2001; Zhang
et al, 2005; Planas-Paz et al, 2012; Lorenz et al, 2018), and since
both proteins appear to partially colocalise on the plasma membrane
of LECs (Fig 3A–D), we investigated whether ILK depletion results
in altered interactions between VEGFR3 and b1 integrin. Notably,
the analysis of VEGFR3/b1 integrin PLA dots in LECs of the jls/pTD
revealed a significantly higher number of interactions in E13.5 ILK
K.O. embryos versus control embryos (Fig 3E–I). Therefore, the
presence of ILK attenuates interactions between VEGFR3 and b1
integrin, thereby inhibiting non-physiologic hyper-activation of
VEGFR3 signalling.
The regulatory role of ILK in lymphatic vascular growth depends
on b1 integrin
In a previous study, we found that endothelial cell-specific deletion
of Itgb1 results in strongly reduced VEGFR3 phosphorylation,
◀ Figure 1. ILK controls lymphatic vascular growth in mouse embryos.A–H E13.5 mouse embryos. (A, E) Bright-field image of a Flk1-Cre;IlkΔ/+ mouse embryo (referred to as “control”) with a heterozygous deletion of Ilk in endothelial cells
and a Flk1-Cre;IlkΔ/Δ embryo (referred to as “ILK K.O.”) with a homozygous deletion of Ilk in endothelial cells. Arrowheads point to oedema. Scale bars: 500 lm. (B–
D, F–H) LSM images of cross-sections through control and ILK K.O. embryos at different developmental stages. Arrows point to the jugular lymph sac/primordial
thoracic duct (jls/pTD). Anterior cardinal vein (acv), dorsal aorta (da), internal jugular vein (ijv) and carotid artery (ca) are also indicated. Scale bars: 100 lm.
I–L LSM images of cross-sections through the jls/pTD of control or ILK K.O. embryos stained for the proliferation marker phospho-Histone H3. Scale bars: 20 lm.
M Number of LECs per jls/pTD section in control or ILK K.O. embryos (n = 3 embryos per genotype at E12.5, E13.0, n = 8 control and n = 7 ILK K.O. embryos at E13.5),
*P = 0.036.
N LEC proliferation as determined by the number of phospho-Histone H3-positive LECs per jls/pTD section in control or ILK K.O. embryos (n = 3 embryos per
genotype at E12.5, E13.0, n = 8 control and n = 7 ILK K.O. embryos at E13.5), *P = 0.042 (control versus ILK K.O. at E13.0), P = 0.058 (control versus ILK K.O. at
E13.5).
Data information: Data are presented as means  SEM, shown as percentage of E12.5 control embryos, unpaired two-tailed Student’s t-test. Unpaired, two-tailed
Mann–Whitney test was additionally performed as a non-parametric test for control versus ILK K.O. at E13.5 in (N), P = 0.094.
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decreased LEC proliferation and a lower LEC number, as well as
significantly smaller jls/pTD during embryonic development
(Planas-Paz et al, 2012). In contrast, we observed the exact opposite
phenotype in ILK K.O. embryos for all mentioned criteria (Figs 1
and 2). Since we found b1 integrin to interact more with VEGFR3 in
the absence of ILK (Fig 3), we deleted an Itgb1 allele to test whether
reduced b1 integrin expression restores physiologic lymphatic
vascular growth in Ilk-deficient mouse embryos (Fig 4). Specifically,
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Figure 2. ILK controls tyrosine phosphorylation of VEGFR3 in mouse embryos.
A–D LSM images of proximity ligation assay (PLA) dots composed of VEGFR3 and phosphorylated tyrosine (p-Tyr) on cross-sections through the jugular lymph sac/
primordial thoracic duct (jls/pTD) of E13.5 control and ILK K.O. embryos. Scale bars: 10 lm.
E–H LSM images of PLA dots composed of VEGFR2 and phosphorylated tyrosine (p-Tyr) on cross-sections through the jls/pTD of E13.5 control and ILK K.O. embryos.
Scale bars: 10 lm.
I Quantification of the PLA dots indicating VEGFR3 with phosphorylated tyrosine (p-Tyr) per LEC of E13.5 control or ILK K.O. embryos (n = 9 embryos per genotype),
*P = 0.022.
J Quantification of the PLA dots indicating VEGFR2 with phosphorylated tyrosine (p-Tyr) per LEC of E13.5 control or ILK K.O. embryos (n = 3 embryos per genotype).
K Quantification of the total number of PLA dots indicating both VEGFR2 (left) and VEGFR3 (right) with phosphorylated tyrosine (p-Tyr) per jls/pTD section of E13.5
control or ILK K.O. embryos (n = 3 embryos per genotype), *P = 0.005 (VEGFR2/p-Tyr in ILK K.O. versus VEGFR3/p-Tyr in ILK K.O.), *P = 0.013 (VEGFR3/p-Tyr in
control versus VEGFR3/p-Tyr in ILK K.O.).
Data information: Data are presented as means  SEM, and in (I, J) data are shown as percentage of control embryos; unpaired two-tailed Student’s t-test (I, J) or two-
way ANOVA with Tukey’s multiple comparisons test (K). Note that not all significances are shown in (K).
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we compared E13.5 embryos with heterozygous deletion of both
Itgb1 and Ilk (referred to as “control”, Fig 4A and B) with embryos
with heterozygous Itgb1 and homozygous Ilk deletion (referred to as
“ILK & b1 integrin K.O.”, Fig 4C and D). Even though more ILK &
b1 integrin K.O. embryos died compared to ILK K.O. embryos, fewer
embryos had oedema or haemorrhages (Appendix Fig S1A and C).
Analysis of the jls/pTD size by quantification of the total LEC
number as well as LEC proliferation, as indicated by phospho-
Histone H3 staining (Fig 4E–H), and VEGFR3 phosphorylation, as
detected by PLA for VEGFR3/p-Tyr (Fig 4I–L), revealed no dif-
ference between control and ILK & b1 integrin K.O. embryos
(Fig 4M–O), indicating a genetic rescue of the lymphatic vascular
A B C D
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Figure 3. ILK controls VEGFR3-b1 integrin interactions in mouse embryos.
A–D LSM images of cross-sections through the jugular lymph sac/primordial thoracic duct (jls/pTD) of an E13.5 control embryo stained for surface VEGFR3 and b1
integrin. Scale bar: 10 lm.
E–H LSM images of proximity ligation assay (PLA) dots (arrows) composed of VEGFR3 and b1 integrin on cross-sections through the jls/pTD of E13.5 control and ILK K.O.
embryos. Scale bars: 10 lm.
I Quantification of VEGFR3/b1 integrin PLA dots normalised to Lyve1-positive area of control or ILK K.O. embryos (n = 6 embryos per genotype), *P = 0.005.
Data information: Data are presented as means  SEM, shown as percentage of control embryos, unpaired two-tailed Student’s t-test.
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phenotype in all analysed parameters. These results suggest that the
regulatory effect of ILK on VEGFR3 signalling, LEC proliferation and
lymphatic vascular growth strictly depends on b1 integrin.
ILK is required to control lymphatic vascular growth in the
adult mouse
To determine whether ILK also regulates VEGFR3 signalling and LEC
proliferation in the adult lymphatic vasculature, we used adult
Prox1-CreERT2 mice to delete Ilk specifically in LECs (Fig 5; Bazigou
et al, 2011). We analysed the lymphatic vascular density of the ear
skin 2 weeks after the last tamoxifen injection (Fig 5A–D), as well as
LEC proliferation (Fig 5E–H) and VEGFR3 phosphorylation as early
as 2 days after the last tamoxifen injection. Thereby, we observed a
significant increase in the dermal lymph vessel density of Prox1-
CreERT2;IlkΔ/Δ mice (referred to as “adult ILK K.O.”) compared to
Prox1-CreERT2;Ilk+/+ mice (referred to as “adult control”) (Fig 5I). In
addition, a significant increase in the number of proliferating LECs in
dermal lymphatic vessels of adult ILK K.O. mice was detected
(Fig 5J), and an ELISA for tyrosine-phosphorylated VEGFR3 indi-
cated a doubled VEGFR3 tyrosine phosphorylation in skin lysates of
adult ILK K.O. mice compared to adult controls (Fig 5K). Next, we
investigated the effect of Ilk deletion on an avascular tissue by
analysing the cornea of adult ILK K.O. mice. Strikingly, we found a
significantly higher number of lymphatic vessels protruding into the
cornea of adult ILK K.O. mice compared to adult controls around
6 weeks after the last tamoxifen injection (Fig 5L–N). Therefore,
even in adult mice, Ilk deletion increases VEGFR3 signalling, LEC
proliferation and lymphatic vascular growth.
ILK regulates lymphatic vascular growth after
myocardial infarction (MI)
Recently published studies revealed the importance of the cardiac
lymphatic vasculature and its remodelling during the recovery phase
after myocardial infarction (MI) (Ishikawa et al, 2007; Klotz et al,
2015; Henri et al, 2016; Tatin et al, 2017). Notably, the importance
of ILK in cardiomyocytes and in regulating cardiac function was
previously reported by several publications (Bendig et al, 2006; Lu
et al, 2006; White et al, 2006; Ding et al, 2009; Gu et al, 2012; Trais-
ter et al, 2012). ILK protein is expressed in LECs sorted from the
adult mouse heart (Appendix Fig S6D); however, to our knowledge,
the function of ILK in cardiac lymphatic vessels has not yet been
analysed. We therefore used adult ILK K.O. mice to first analyse the
lymphatic vasculature in the heart 2 weeks after the last tamoxifen
injection (Fig 6A–D). While we observed a significant upregulation
of the cardiac lymph vessel density by 39% (*P = 0.019) within
lateral regions of the ventricles (Fig 6A and B), we only saw a non-
significant increase when quantifying the lymph vessel density in
total heart sections (Fig 6C), while the blood vessel density was
virtually unchanged (Fig 6D). The data suggest that ILK regulates
lymphatic vascular growth in the adult myocardium, but its regula-
tory strength might depend on the location of lymphatic vessels,
which were recently described to be anatomically and morphologi-
cally heterogeneous in the heart (Norman & Riley, 2016; Tatin et al,
2017).
Next, we analysed the cardiac lymph vessel density in adult ILK
K.O. mice versus control mice after MI. Two weeks after the last
tamoxifen injections, the mice underwent an occlusion of the left
▸Figure 5. ILK controls lymphatic vascular growth and VEGFR3 tyrosine phosphorylation in adult mice.A–D LSM images of a whole-mount stained adult Prox1-CreERT2;Ilk+/+ mouse ear (referred to as “adult control”) and Prox1-CreERT2;IlkΔ/Δ mouse ear (referred to as “adult
ILK K.O.”), with higher magnification images indicated by dashed lines. Scale bars: 500 and 100 lm, respectively.
E–H LSM images of a whole-mount stained adult control and ILK K.O. ear, with higher magnification images indicated by dashed lines. Arrows point to proliferating
LECs. Scale bars: 100 and 20 lm, respectively.
I Dermal lymph vessel density as determined by VEGFR3-positive area normalised to the total analysed area of adult control or ILK K.O. mice (n = 4 control and
n = 5 ILK K.O. mice), *P = 0.025.
J LEC proliferation as determined by phospho-Histone H3-positive LECs normalised to analysed VEGFR3-positive area in the skin of adult control or ILK K.O. mice
(n = 7 control and n = 5 ILK K.O. mice), *P = 0.004.
K VEGFR3 tyrosine phosphorylation as determined by ELISA of skin lysates of adult control or ILK K.O. mice (n = 3 mice per genotype), P = 0.062.
L, M LSM images of a whole-mount stained adult control and ILK K.O. cornea, with detailed images on their right (L0 , M0). Arrows point to lymph vessels protruding into
the cornea (encircled by a dotted line). Scale bars: 500 lm and 100 lm, respectively.
N Number of lymph vessels in control or ILK K.O. corneas (n = 5 and n = 7 corneas), *P = 0.02.
Data information: Data are presented as means  SEM, shown as percentage of control mice, unpaired two-tailed Student’s t-test.
◀ Figure 4. The lymphatic vascular effect of Ilk deletion strictly depends on b1 integrin.A, B Bright-field image of an E13.5 Flk1-Cre;IlkΔ/+;Itgb1Δ/+ mouse embryo (referred to as “control”) with a heterozygous deletion of both Ilk and Itgb1 in endothelial cells,
and a LSM image of a stained cross-section through its jugular lymph sac/primordial thoracic duct (jls/pTD). Scale bars: 500 and 100 lm, respectively.
C, D Bright-field image of an E13.5 Flk1-Cre;IlkΔ/Δ;Itgb1Δ/+ embryo (referred to as “ILK & b1 integrin K.O.”), with a homozygous deletion of Ilk and heterozygous deletion
of Itgb1 in endothelial cells, and a LSM image of a stained cross-section through its jls/pTD. Scale bars: 500 and 100 lm, respectively.
E–H LSM images of cross-sections through the jls/pTD of E13.5 control and ILK & b1 integrin K.O. embryos stained for the proliferation marker phospho-Histone H3.
Arrows point to phospho-Histone H3-positive LECs. Scale bars: 20 lm.
I–L LSM images of PLA dots composed of VEGFR3 and phosphorylated tyrosine (p-Tyr) on stained cross-sections through the jls/pTD of control and ILK & b1 integrin
K.O. embryos. Arrows point to PLA dots within the Lyve1-stained area. Scale bars: 10 lm.
M Number of LECs per jls/pTD section in E13.5 control or ILK & b1 integrin K.O. embryos.
N LEC proliferation as determined by the number of phospho-Histone H3-positive LECs per jls/pTD section in E13.5 control or ILK & b1 integrin K.O. embryos.
O Quantification of the PLA dots indicating VEGFR3 with phosphorylated tyrosine (p-Tyr) per LEC of E13.5 control or ILK & b1 integrin K.O. embryos.
Data information: Data are presented as means  SEM, shown as percentage of control embryos with n = 5 embryos per genotype, unpaired two-tailed Student’s t-test.
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anterior descending coronary artery (LAD) for 60 min, resulting in
myocardial ischaemia, followed by reperfusion of the LAD (Fig 6E–
H) (Nossuli et al, 2000). Around 4 weeks after MI, adult ILK K.O.
mice revealed a higher cardiac lymph vessel density compared to
that of control mice, while the cardiac blood vessel density was
lower (Fig 6G and H). Notably, the fraction of CD68-positive macro-
phages in the Lyve1-positive area was unchanged in ILK K.O. versus
control mice and only accounted for around 1% of the total cardiac
Lyve1-positive area after MI (Appendix Fig S10A–I). These observa-
tions suggest that ILK controls cardiac lymph vessel density after
MI.
ILK controls LEC proliferation, VEGFR3 signalling and interactions
between VEGFR3 and b1 integrin in adult human LECs
Finally, we aimed to reproduce our results on ILK in the human
system. Therefore, we transfected primary human LECs with
either a control siRNA (referred to as “control”) or one of three
different siRNAs against ILK (referred to as “ILK-1”, “ILK-2” and
“ILK-3”) and analysed the knockdown (KD) efficiency at both
the mRNA and protein level (Appendix Fig S11). ILK mRNA
levels were reduced by up to 85% (Appendix Fig S11A), while
ILK protein was downregulated by up to 80% (Appendix Fig
S11B and C). Next, we performed BrdU incorporation assays to
analyse LEC proliferation upon ILK KD (Fig 7A–C). Consistent
with our in vivo results, we observed significantly increased
proliferation in human LECs upon ILK KD (Fig 7C). Analysis of
VEGFR3 phosphorylation in human LEC lysates was performed
by ELISA and showed a significantly increased tyrosine phospho-
rylation of human VEGFR3 when ILK was silenced (Fig 7D).
Further, we performed PLA experiments with human LECs to
analyse interactions between VEGFR3 and b1 integrin. In line
with the in vivo data, we observed an increased number of PLA
dots (normalised to the number of analysed LECs) upon silencing
of ILK (Fig 7E–G).
Mechanical stretch of adult human LECs results in dissociation of
ILK from b1 integrin and reduced expression of a-parvin
Recently, we found that mechanotransduction in LECs results in
enhanced VEGFR3 signalling and LEC proliferation in a b1 inte-
grin-dependent manner in vivo and in vitro (Planas-Paz et al,
2012). To show that mechanical stimulation of LECs leads to
interaction of b1 integrin and VEGFR3 (Planas-Paz et al, 2012),
similar to ILK depletion, adult human LECs were mechanically
stretched and subsequently analysed for VEGFR3/b1 integrin
interaction. Notably, significantly more VEGFR3/b1 integrin PLA
dots were detected in mechanically stretched versus unstretched
LECs (Fig 8A–E). Next, we analysed the effect of mechanical
stimulation on the interaction between ILK and b1 integrin by co-
immunoprecipitation (Co-IP) assays, in which we used HA-tagged
b1 integrin for IP with subsequent detection of ILK in the IP
lysates via Western blotting (Fig 8F, G). The anti-HA antibody
selectively precipitated b1 integrin compared to the IgG control
antibody, and more ILK protein was found to be precipitated
using anti-HA antibodies compared to control IgG antibodies
(Appendix Fig S12A–C). Even though only small amounts of ILK
could be precipitated with HA-tagged b1 integrin, we observed a
significant reduction in ILK protein associated with b1 integrin in
LEC lysates after mechanical stimulation (Fig 8G).
We next analysed the effect of mechanical stretching on the
expression of ILK and a-parvin protein, and found no substantial
reduction in ILK protein levels upon stretching human LECs
(Appendix Fig S12D and E). In contrast, protein levels of a-
parvin (as an F-actin binding protein of the IPP complex) were
significantly reduced (Appendix Fig S12F). Similar to the
mechanical stimulation, knockdown of ILK significantly reduced
a-parvin protein levels (Fig EV5A–C), whereas PARVA knock-
down did not substantially affect ILK protein expression
(Fig EV5D–F), suggesting ILK is upstream of a-parvin. The
results indicate that in the absence of mechanical stimulation,
the assembly of ILK (as part of the IPP complex) and b1 inte-
grin attenuates the interaction of b1 integrin with VEGFR3 and
thus prevents non-physiologic VEGFR3 activation and LEC pro-
liferation.
Discussion
VEGFR3 is a highly mechanoresponsive RTK (Planas-Paz et al,
2012; Baeyens et al, 2015; Coon et al, 2015; Choi et al, 2017a;
Lorenz et al, 2018), and b1 integrin is critically required for full
VEGFR3 activation (Wang et al, 2001; Galvagni et al, 2010;
Planas-Paz et al, 2012). Surprisingly, we identified ILK and b1
integrin to have opposing roles in VEGFR3 signalling and
lymphatic vascular growth. Based on our genetic, cell biological
and biochemical results we obtained using primary human LECs,
as well as embryonic and adult mice, we propose a novel molec-
ular mechanism of how b1 integrin-mediated VEGFR3 signalling
is regulated endogenously in order to prevent excessive lymphatic
▸Figure 6. ILK controls lymphatic vascular growth in the heart after myocardial infarction.A, B LSM images of cross-sections through the heart of an adult Prox1-CreERT2;Ilk+/+ mouse (referred to as “adult control”) and Prox1-CreERT2;IlkΔ/Δ mouse (referred to as
“adult ILK K.O.”) showing the outer lateral region of the left ventricle (LV). Scale bars: 100 lm.
C, D Overall cardiac lymph vessel and blood vessel density in heart sections as determined by Lyve1-positive and CD31-positive area (normalised to total analysed
myocardial area), respectively (n = 4 control and n = 5 ILK K.O. mice).
E, F LSM images of cross-sections through the heart of an adult control and ILK K.O. mouse 4 weeks after myocardial ischaemia and reperfusion (MI/R), showing the
outer lateral region of the LV. Scale bars: 100 lm.
G, H Overall cardiac lymph vessel and blood vessel density in heart sections as determined by Lyve1-positive and CD31-positive area (normalised to total analysed
myocardial area), respectively (n = 5 control and n = 7 ILK K.O. mice), P = 0.051 (cardiac lymph vessel density in adult control or adult ILK K.O.), *P = 0.025 (cardiac
blood vessel density in adult control or adult ILK K.O.).
Data information: Data are presented as means  SEM, shown as percentage of control mice, unpaired two-tailed Student’s t-test.
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VEGFR3/β1 integrin PLA Nuclei
Control siRNA ILK-3 siRNA
Figure 7. ILK controls proliferation, VEGFR3 signalling and VEGFR3-b1 integrin interactions in human LECs.
A, B Images of adult human LECs after 1 h of BrdU incorporation and previous transfections with control or ILK siRNA. Scale bars: 50 lm.
C LEC proliferation as determined by the number of BrdU-positive cells normalised to the total number of LECs previously transfected with control siRNA or ILK
siRNAs in the presence of VEGF-C Cys156Ser (n = 3 independent transfections per siRNA), *P = 0.032 (control versus ILK-1), *P = 0.005 (control versus ILK-2),
*P = 0.0003 (control versus ILK-3).
D VEGFR3 tyrosine phosphorylation as determined by ELISA of lysates from adult human LECs transfected with control siRNA or ILK siRNAs in the presence of VEGF-C
Cys156Ser (n = 4 (control siRNA, ILK-1 siRNA and ILK-3 siRNA) or n = 8 (ILK-2 siRNA) independent transfections per siRNA), *P = 0.0001 (control versus each siRNA).
E, F LSM images of VEGFR3/b1 integrin PLA dots in human LECs transfected with control or ILK siRNA. Scale bars: 10 lm.
G Quantification of VEGFR3/b1 integrin PLA dots per human LEC after transfection with control siRNA or ILK siRNAs (n = 5 independent transfections per siRNA),
P = 0.234 (control versus ILK-1), *P = 0.024 (control versus ILK-2), *P = 0.001 (control versus ILK-3).
Data information: Data are presented as means  SEM, shown as percentage of control siRNA, one-way ANOVA with Dunnett’s multiple comparisons test.
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Adult human LECs upon mechanical stretch
































































































Figure 8. Mechanically stretched human LECs have more VEGFR3-b1 integrin and less ILK-b1 integrin interactions.
A–D LSM images of PLA dots in human LECs that were kept unstretched or mechanically stretched for 30 min. Red dots are PLA dots composed of VEGFR3 and b1
integrin. Scale bars: 10 lm.
E Quantification of VEGFR3/b1 integrin PLA dots per human LEC with (+) or without () mechanical stretch (n = 6 independent stretch chambers), *P = 0.039.
F Western blot (WB) image of human LECs that were either kept unstretched or stretched for 30 min and used for immunoprecipitation (IP) of HA-tagged b1 integrin
from whole cell lysates with subsequent detection of interacting ILK in IP lysates.
G Quantification of the ILK protein amount in IP lysates from LECs with (+) or without () mechanical stretch; normalised to the respective amount of HA-tagged b1
integrin (n = 3 (unstretched) or n = 5 (stretched) independent stretch chambers), *P = 0.0007.
Data information: Data are presented as means  SEM, unpaired two-tailed Student’s t-test.
Source data are available online for this figure.
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vascular growth (Fig 9). In the absence of mechanical stimula-
tion, ILK attenuates interaction between VEGFR3 and b1 integrin,
likely with other IPP complex members, such as a-parvin
(Fig 9A), which was shown to be one of the strongest interaction
partners of ILK (Dobreva et al, 2008), and is known to interact
with the F-actin cytoskeleton (Nikolopoulos & Turner, 2000; Olski
et al, 2001). The interaction between ILK and b1 integrin may be
direct or indirect (e.g. via Kindlin-2) (Hannigan et al, 1996;
Montanez et al, 2008; Horton et al, 2015; Kadry et al, 2018).
Upon mechanical stimulation of LECs—such as during increased
interstitial fluid accumulation when the LECs are stretched—ILK
dissociates from b1 integrin (Fig 9B), thereby facilitating the inter-
action of b1 integrin with VEGFR3 (Fig 9C). This molecular inter-
action increases VEGFR3 tyrosine phosphorylation, LEC
proliferation and lymphatic vascular growth (Planas-Paz et al,
2012). Notably, similar to mechanical stimulation, loss of ILK
results in increased interaction between VEGFR3 and b1 integrin,
reduced a-parvin expression and leads to strongly upregulated
VEGFR3 signalling, as well as LEC proliferation, causing
lymphatic vascular growth (Fig 9D).
Lymphatic network formation requires a careful balance of pro-
and anti-lymphangiogenic regulators (reviewed by Schulte-Merker
et al, 2011; Klein & Caron, 2015; Sabine et al, 2016). Disturbing
this balance leads to hypo- or hyperplasia of lymphatic vessels,
which is of clinical importance across multiple pathologies
(Rutkowski et al, 2006; Klotz et al, 2015; Gousopoulos et al, 2016,
2017; Henri et al, 2016; Tatin et al, 2017). Here, we identified ILK
to be required to limit VEGFR3 signalling and lymphatic vascular
growth in developmental, physiological and pathological condi-
tions. Without ILK, the lymphatic vasculature undergoes excessive
growth, which is rescued by decreasing the expression of b1 inte-





































Figure 9. Simplified model of mechanosensitive VEGFR3 signalling and ILK-controlled lymphatic vascular growth.
A In quiescent LECs, VEGFR3 and b1 integrin are physically separated. ILK directly or indirectly interacts with b1 integrin and connects it to the F-actin cytoskeleton via
intracellular proteins, such as a-parvin, a component of the IPP complex.
B Upon mechanical stretch, the complex of b1 integrin and ILK (along with the entire IPP complex) transiently disrupts.
C This releases b1 integrin, resulting in its interaction with VEGFR3, and thus in increased VEGFR3 tyrosine phosphorylation (“P” in yellow circle). As a consequence, LEC
proliferation and lymphatic vascular growth are induced.
D The absence of ILK results in permanent interaction between VEGFR3 and b1 integrin, leading to upregulated VEGFR3 tyrosine phosphorylation (“P” in yellow circle),
LEC proliferation and non-physiologic lymphatic vascular growth.
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VEGFR3, ILK facilitates translation of mechanical cues into cellular
responses (Fig 9A–C), which are essential for the controlled devel-




C57Bl/6J (Janvier) mouse embryos were used for wild-type studies.
Flk1-Cre mice and Ilk-loxP mice have been separately described
previously (Sakai et al, 2003; Licht et al, 2004). For additional
genetic deletion of Itgb1, these mice were crossed with Itgb1-loxP
mice (Potocnik et al, 2000). For lymphatic endothelial cell (LEC)-
specific deletion of Ilk, we used Prox1-CreERT2 mice (Bazigou et al,
2011). Embryos with endothelial cell-specific Parva deletion were
generated by crossings of Tie2-Cre mice (Kisanuki et al, 2001) and
Parva-loxP mice (Montanez et al, 2009; Fraccaroli et al, 2015). In
general, littermates or mouse embryos with a similar genetic back-
ground served as controls. Adult female Prox1-CreERT2 mice and Ilk-
loxP mice at the age of 15–25 weeks (age-matched within each
experiment) were used to analyse the effect of Ilk deletion in LECs.
To induce Cre-mediated recombination in Prox1-CreERT2 and Prox1-
CreERT2;Ilk-loxP embryos, pregnant mice were given intraperitoneal
tamoxifen (Sigma, T5648, solved in peanut oil) injections (40 mg/
kg) for two consecutive days at the embryonic stage E11.0 and
E12.0, while adult mice were given six consecutive tamoxifen injec-
tions (40 mg/kg). Adult tissues were collected and analysed 2 days,
2 or 6 weeks after the last tamoxifen injection, as indicated in the
results.
Myocardial infarction
For the induction of myocardial ischaemia, Prox1-CreERT2 and
Prox1-CreERT2;Ilk-loxP mice were subjected to a temporary ligation
of the left anterior descending coronary artery (LAD) for 60 min,
followed by reperfusion. For the surgical procedures, a closed-
chest model was chosen to reduce inflammatory reactions that
are due to the surgical trauma itself (Nossuli et al, 2000). There-
fore, mice underwent a pre-surgery 1 week after the last tam-
oxifen injection, in which the suture was placed underneath the
LAD, in principle following the detailed protocol described in
Merx et al (2014). Briefly, mice were anesthetised by intra-
peritoneal injections of ketamine (100 mg/kg bodyweight,
Ketanest S, Pfizer Pharma GmbH) and xylazine (10 mg/kg body-
weight, RompunTM, Bayer Healthcare), followed by respiration
with isoflurane (2.0 vol.%, Piramal Healthcare). A 7-0 surgical
suture (Ethicon, Johnson and Johnson) was carefully passed
underneath the LAD at a position around 1 mm from the tip of
the left auricle, and the ends of the suture were threaded through
a PE tubing and placed in the subcutaneous tissue pocket. Liga-
tion of the LAD to induce myocardial ischaemia was performed
1 week after the pre-surgery. Therefore, mice were re-anesthetised
with isoflurane (3.0 vol.%), the skin was opened, and ischaemia
was induced by gently pulling the suture ends affixed to metal
picks apart until ST elevation was seen on the electrocardiogra-
phy (ECG). 60 min later, reperfusion was confirmed by resolution
of ST elevation. Mice were harvested around 4 weeks after MI
and used for analyses of the cardiac lymphatic vasculature, as
well as for corneal lymphangiogenesis studies.
Magnetic-activated cell sorting
Whole mouse hearts or jugular regions of mouse embryos were
isolated and immediately dissociated using the gentleMACSTM
Dissociator (Miltenyi Biotec), as described in Planas-Paz et al
(2012) and the customer protocol by Miltenyi Biotec (“Isolation
of lymphatic endothelial cells (LECs) from mouse embryos using
the gentleMACSTM Dissociator”). Briefly, cell suspensions were
labelled with rat anti-mouse PECAM-1-FITC clone 390 (Millipore,
CBL1337F) and rabbit anti-mouse Lyve-1 (Abcam, ab14917) anti-
bodies or goat anti-mouse Lyve-1 (R&D Systems, AF2125) anti-
bodies that were previously conjugated to magnetic Microbeads
using the MACSflex MicroBead Kit according to the manufac-
turer’s protocol (Miltenyi Biotec, 130-105-805). LECs were sorted
in a stepwise manner using anti-FITC MultiSort microbeads (Mil-
tenyi Biotec, 130-058-701), followed by goat anti-rabbit IgG
microbeads (Miltenyi Biotec, 130-048-602) or self-conjugated goat
anti-Lyve1 microbeads (R&D Systems, AF2125; Miltenyi Biotec,
130-105-805). Subsequently, sorted LECs were either homogenised
with peqGold TriFast (Peqlab) for quantitative real-time PCR or
frozen for Western blotting.
Immunohistochemistry of embryonic sections
Embryos were fixed in 4% PFA (Chemsolute, TH. Geyer) overnight
(at 4°C), stepwise cryopreserved in 15 and 30% sucrose (Sigma)
overnight (at 4°C), embedded in Tissue Tek O.C.T. embedding media
(Thermo Fisher Scientific) and transversally separated into 12-lm
cryosections. Specifically, all sections from beginning of the embry-
onic neck region to the beginning of the heart were collected consec-
utively on SuperFrost slides (Thermo Fisher Scientific), so that the
whole jugular lymph sacs/primordial thoracic ducts (jls/pTD) region
was present on each slide. For quantification of total LEC numbers
per jls/pTD section, only sections of centrally located, lumenised jls/
pTD were analysed, while LEC proliferation was determined by
counting proliferating LECs on sections through the entire jls/pTD
regions. Quantification of total LECs or proliferating LECs was subse-
quently normalised to the number of analysed sections. Proliferation
of blood vascular endothelial cells (BECs) was quantified in the
embryonic region around the jls/pTD and normalised to the DAPI-
positive area. The following antibodies were used for immunostain-
ings: goat anti-mouse Lyve-1 (R&D Systems, AF2125), rabbit anti-
mouse Lyve-1 (Abcam, ab14917), goat anti-human Prox1 (R&D,
AF2727), goat anti-mouse VEGFR3 (R&D Systems, AF743), rabbit
anti-mouse VEGFR2 clone 55B11 (Cell Signaling, 2479), rat anti-
mouse CD31/PECAM-1 (BD Bioscience, 553370), rabbit anti-
phospho-Histone H3 (Millipore, 06-570), rabbit anti-Ki67 (Merck
Millipore, AB9260) and rat anti-activated b1 integrin clone 9EG7 (BD
Bioscience, 553715). For surface VEGFR3/b1 integrin staining, fixed
mouse embryonic sections were incubated with goat anti-mouse
VEGFR3 antibody (R&D Systems, AF743) without any detergent,
while they were washed thoroughly afterwards, and incubated with
rat anti-b1 integrin clone MB1.2 (Merck Millipore, MAB1997) in the
presence of detergent (0.2% Triton X-100, AppliChem). Secondary
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antibodies conjugated with AF488, AF555 (Molecular Probes), Cy3
or Cy5 (Jackson ImmunoResearch) were used. DAPI (Sigma) was
used to counterstain cell nuclei. All images were acquired using
Laser Scan Microscopy (LSM 710, Zeiss) and analysed using the
ImageJ software.
Immunohistochemistry of adult mouse sections
Adult mouse hearts were fixed in 4% PFA (Chemsolute, TH. Geyer)
overnight (at 4°C), stepwise cryopreserved in 15 and 30% sucrose
(Sigma) overnight (at 4°C), embedded in Tissue Tek O.C.T. embed-
ding media (Thermo Fisher Scientific) and transversally separated
into consecutive 12-lm cryosections on SuperFrost slides (Thermo
Fisher Scientific). The following antibodies were used for immuno-
staining: goat anti-mouse Lyve-1 (R&D Systems, AF2125), rabbit
anti-mouse Lyve1 (Abcam, ab14917), rat anti-mouse CD31/PECAM-
1 (BD Bioscience, 553370), goat anti-CD31 (R&D Systems, AF3628),
rabbit anti-Prox1 (Proteintech, 11067-2-AP) and rat anti-CD68 (Invit-
rogen, 14-0681-82). Secondary antibodies conjugated with AF488
(Molecular Probes), Cy3 or Cy5 (Jackson ImmunoResearch) were
used. DAPI (Sigma) was used to counterstain cell nuclei. All images
were acquired using Laser Scan Microscopy (LSM 710, Zeiss) and
analysed using the ImageJ software.
Whole-mount staining of embryonic and adult mouse tissues
For whole-mount staining, whole embryos were fixed in 4% PFA
(Chemsolute, TH. Geyer) overnight (at 4°C), and skins were gently
removed. Adult mouse ears were collected and tissue layers gently
separated. The inner ear layer was fixed in 4% PFA (Chemsolute,
TH. Geyer) overnight (at 4°C), and the internal-facing side was
imaged. For corneal lymphangiogenesis analyses, mouse corneas
were collected and fixed in acetone (VWR) for 20 min (at RT). The
following antibodies were used for whole-mount stainings: goat
anti-mouse VEGFR3 (R&D Systems, AF743), rabbit anti-phospho-
Histone H3 (Millipore, 06-570), goat anti-Lyve1 (R&D Systems,
AF2125) and rat biotin anti-mouse CD31 (BioLegend, 102504).
Secondary antibodies conjugated with AF488 (Molecular Probes) or
Cy3 (Jackson ImmunoResearch) were used. DAPI (Sigma) was used
to counterstain cell nuclei. All images were acquired using Laser
Scan Microscopy (LSM 710, Zeiss) and analysed using the ImageJ
software. Quantification of the dermal lymph vessel size in mouse
embryos was performed by determining Lyve1-positive area with
exclusion of macrophages and normalisation to the number of
lymph vessels per image. For analysis of dermal lymph vessel densi-
ties in adult mice, a tile scan of the whole ear skin was performed;
the central region was subsequently analysed for VEGFR3-positive
area, which was normalised to the total analysed area. For analysis
of proliferating LECs in the skin, the number of phospho-Histone
H3-positive cells was normalised to the VEGFR3-positive area per
image. For corneal lymphangiogenesis studies, a tile scan of the
whole mouse cornea was performed, and the total number of
lymphatic vascular sprouts protruding into the cornea was counted.
Cell culture and transfections
All in vitro experiments were performed with adult human dermal
microvascular lymphatic endothelial cells (LECs) (Promocell or
Lonza). These cells were not found in the database of commonly
misidentified cell lines that are maintained by ICLAC and NCBI
BioSample. Cells were authenticated by stimulation with 100 ng/ml
VEGF-C Cys156Ser (R&D Systems) and subsequent detection of
VEGFR3 phosphorylation. Cells were also tested negative for myco-
plasma contamination. For experiments, LECs were grown in
endothelial cell growth medium MV2 (Promocell or Lonza) and
used at passages ≤ P6. All cell culture dishes were coated with fibro-
nectin (2.5 lg/cm2, human plasma fibronectin purified protein,
Millipore).
Cell stretch studies were performed by growing cells on STREX
stretch chambers (BioCat, ST-CH-04-BR) for 24 or 48 h, and then
stretching them for 30, 60 or 120 min (Planas-Paz et al, 2012).
Afterwards, cells were either immediately fixed in 4% PFA and used
for proximity ligation assays or lysed for co-immunoprecipitation
assays or Western blotting.
To achieve an ILK knockdown, cells were transfected with 250–
500 nM stealth siRNAs against human ILK (Invitrogen): ILK-1 50-
GCCUGUGGCUGGACAACACGGAGAA-30, ILK-2 50-CAGCCAGUCAU
GGACACCGUGAUAU-30 and ILK-3 50GCAUUGACUUCAAACAGCUU
AACUU-30, or non-targeting control siRNAs (Invitrogen) with a simi-
lar GC content, and incubated for 48–72 h. To achieve a PARVA
knockdown, cells were transfected with 150 nM stealth siRNAs
against human a-parvin (Invitrogen): PARVA-1 50-CAAGCUGAAU
GUGGUGAAA-30, PARVA-2 50-CCUGAAAUCUACACUACGA-30 and
PARVA-3 50-GAACUGAUGAAGGUAUUAA-30, or non-targeting
control siRNAs (Invitrogen) with a similar GC content, and incu-
bated for 48 h. For analysis of knockdown efficiencies, quantitative
real-time PCR or Western blotting was performed. For co-immuno-
precipitation assays, LECs were transfected with 1 lg C-terminally
human influenza hemagglutinin (HA)-tagged b1 integrin plasmid
(Sino Biological, HG10587-CY) and subsequently cultured on stretch
chambers. All transfections were performed using the Nucleofec-
torTM 2b Device or the 4D-NucleofectorTM System (Lonza).
Co-immunoprecipitation (Co-IP) and Western blotting
48 hours after HA-tagged b1 integrin plasmid transfection, LECs
were stretched for 30 min and subsequently collected in ice-cold
lysis buffer containing 50 mM HEPES pH 7.0, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 1 mM activated Na3VO4, phosphatase
inhibitors (Phosphatase Inhibitor Cocktail, Roche or Sigma-
Aldrich) and protease inhibitors (cOmplete, Protease Inhibitor
Cocktail Tablets, Roche). Protein concentrations were determined
by using the PierceTM BCA Protein Assay (Thermo Fisher Scien-
tific). Equal amounts of protein (200-300 lg) were used for a pre-
clearing step (1 h at 4°C) of the lysates with 30 ll Protein G Plus/
Protein A Agarose Suspension (Millipore, IP05-1.5 ml). For
immunoprecipitation, pre-cleared lysates were incubated with 3 ll
rabbit anti-HA tag antibody (Cell Signaling, 3724) or equal concen-
tration of normal rabbit IgG (Cell Signaling, 2729) overnight (at
4°C), followed by another incubation with 30 ll Protein G Plus/
Protein A Agarose Suspension for 3 h (at 4°C). After supernatants
were removed, beads were washed with IP lysis buffer, and
samples were analysed via Western blotting. In general, Western
blotting was performed for Co-IP analyses, determination of
knockdown efficiencies or protein levels after cell stretch studies,
as well as for analysis of MACS-sorted LECs. Therefore, samples
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were collected in Laemmli buffer containing 10 mM NaF, 1 mM
activated Na3VO4, protease inhibitors (complete, Protease Inhibitor
Cocktail Tablets, Roche), phosphatase inhibitors (Phosphatase
Inhibitor Cocktail, Sigma-Aldrich), 1x Laemmli (Bio-Rad) and 1%
2-Mercaptoethanol (Roth). The Invitrogen Novex Mini-Cell Device
(Thermo Fisher Scientific) or the Mini-PROTEAN Tetra Cell
Device (Bio-Rad) was used for protein separation. For Western
blotting, the Trans-Blot Turbo Transfer System (Bio-Rad) and
following antibodies were used: rabbit anti-ILK (Cell Signaling,
3862), rabbit anti-a-parvin (Cell Signaling, 4026) and rabbit anti-
GAPDH (Abcam, ab9485) for the determination of knockdown
efficiencies or cell stretch studies, rabbit anti-HA tag (Cell Signal-
ing, 3724) and mouse anti-ILK (BD Biosciences, 611803) for Co-IP
studies and rabbit anti-Prox1 (Proteintech, 11067-2-AP) and rabbit
anti-ILK (Cell Signaling, 3862) for analysis of MACSed LECs.
Normal rabbit IgG (Cell Signaling, 2729) was used as control in
IPs and Western blots. ILK and PARVA knockdown efficiencies
after siRNA transfections were determined by normalisation of ILK
or a-parvin protein amount to their respective GAPDH protein
amount, while the amount of ILK protein detected in the IP lysates
was normalised to the respective HA-tagged b1 integrin protein
amount during quantification.
In vitro proliferation assay
To analyse human LEC proliferation, cells were starved overnight in
basal medium without growth factors (EBM-2 MV, Promocell or
Lonza), washed with PBS and incubated with 100 ng/ml VEGF-C
Cys156Ser (R&D Systems) and 10 lM 5-bromo-20-deoxyuridine
(BrdU, Sigma) for 1 h. Cells were washed with PBS, immediately
fixed in ethanol fixative (70% ethanol, 30% glycine 50 nM), and
staining was performed with mouse anti-BrdU antibody (BD
Bioscience, 555627). Secondary antibody conjugated with AF488
(Molecular probes) was used, as was DAPI (Sigma) to counterstain
cell nuclei. Imaging was performed by using fluorescence micro-
scopy (Nikon Eclipse Ti-S) and analysed with the ImageJ software.
For analysis of proliferating human LECs, 10 images were taken
from cells per transfection, and the number of BrdU-positive cells
was divided by the total cell number to determine proliferation
rates.
ELISA
To determine VEGFR3 phosphorylation in mouse skin lysates, ears
were collected and the inner ear layer was immediately homoge-
nised in ice-cold lysis buffer containing 50 mM HEPES pH 7.0,
150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM activated
Na3VO4, phosphatase inhibitors (Phosphatase Inhibitor Cocktail,
Roche or Sigma-Aldrich) and protease inhibitors (cOmplete,
Protease Inhibitor Cocktail Tablets, Roche). For analysis of human
VEGFR3 phosphorylation, cells were starved overnight in basal
medium without growth factors (EBM-2 MV, Promocell or Lonza),
washed with PBS and stimulated for 5 min with 100 ng/ml VEGF-C
Cys156Ser (R&D Systems). After washing in PBS, cells were immedi-
ately lysed in the same ice-cold lysis buffer. Protein concentrations
were determined by using the PierceTM BCA Protein Assay (Thermo
Fisher Scientific). Equal amounts of protein were loaded on the
ELISA. VEGFR3 phosphorylation was detected by using the DuoSet
IC human phospho-VEGFR3 ELISA (R&D Systems) according to the
manufacturer’s protocol. In addition, tissue lysates were normalised
to total VEGFR3 amounts using the DuoSet IC human total VEGFR3
ELISA (R&D Systems).
Proximity ligation assay
Proximity ligation assays were performed to determine tyrosine
phosphorylation of VEGFRs or protein interactions (Soderberg et al,
2006) according to the manufacturer’s protocol using the Duolink
in situ reagents (Olink Bioscience). The following antibodies
were used on embryonic sections: goat anti-mouse VEGFR3 (R&D
Systems, AF743), rabbit anti-mouse VEGFR2 clone 55B11 (Cell
Signaling, 2479), mouse anti-phospho-tyrosine 4G10 Platinum (Mil-
lipore, 05-1050) and rat anti-mouse b1 integrin clone MB1.2 (Milli-
pore, MAB1997). The following antibodies were used for in vitro
PLA studies: goat anti-human VEGFR3 (R&D Systems, AF349) and
mouse anti-human b1 integrin (Millipore, MAB1987). Co-stainings
were performed using rabbit anti-mouse Lyve-1 (Abcam, ab14917)
or Alexa Fluor488 phalloidin (Invitrogen by Thermo Fisher,
A12379). Secondary antibodies conjugated with AF488 (Molecular
Probes) were used, as well as DAPI (Sigma) to counterstain cell
nuclei. All images were acquired using Laser Scan Microscopy
(LSM 710, Zeiss) and analysed using the ImageJ software. PLA dots
were normalised to the number of LECs or to the Lyve1-positive
area.
Quantitative real-time PCR
Total RNA was isolated using the phenol/chloroform extraction
method (Chomczynski & Sacchi, 1987). cDNA was synthesised
using SuperScriptTMII Reverse Transcriptase (Invitrogen by Thermo
Fisher Scientific). The following primers were used:
mouse Ilk forward 50-GTGGCTGGACAACACAGAGA-30,
mouse Ilk reverse 50-ATCCCCACGATTCATCACAT-30,
mouse beta-2 microglobulin (B2m) forward 50-GAGCCCAAGA
CCGTCTACTG-30,
mouse B2m reverse 50-GCTATTTCTTTCTGCGTGCAT-30,
human ILK forward 50-AAGGTGCTGAAGGTTCGAGA-30,
human ILK reverse 50-ATACGGCATCCAGTGTGTGA-30,
human B2M forward 50-TTTCATCCATCCGACATTGA-30,
human B2M reverse 50-CCTCCATGATGCTGCTTACA-30.
Quantitative real-time PCR was performed by using the LightCycler
Nano Device (Roche). All experiments were performed in duplicates
or triplicates.
Statistical analysis
Statistical significance was determined by using Excel (Microsoft) or
Prism software (GraphPad Inc.). Normal distribution of data was
tested with the Shapiro–Wilk normality test for sample sizes of
n ≥ 7. Unpaired two-tailed Student’s t-test (with Welch’s correction)
was performed for comparisons of two groups, while one-way
ANOVA followed by Tukey or Dunnett post hoc test or two-way
ANOVA followed by Tukey post hoc test was performed for multi-
ple comparisons. Additional non-parametric tests were used for not
normally distributed data, in particular the unpaired, two-
tailed Mann–Whitney test for comparisons of two groups or the
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Kruskal–Wallis test followed by Dunn’s post hoc test for multiple
comparisons. Differences were considered significant with a
P < 0.05, and P < 0.0001 are stated as P = 0.0001. Quantified data
are presented as means  standard error of the mean (SEM). No
statistical method was used to predetermine sample size. The
experiments were not randomised, but investigators were blinded
to allocation during some experiments and outcome assessment.
Significant outliers were detected by the extreme studentized
deviate method (Grubbs’ test) for n ≥ 4 embryos, mice or
samples, and excluded from the statistical analysis. In addition,
adult mice with morphological abnormalities were excluded from
the statistical analysis.
Study approval
All animal experiments were approved by the local Animal Ethics
Committee of the Landesamt für Natur, Umwelt und Verbraucher-
schutz Nordrhein-Westfalen (LANUV North Rhine-Westphalia,
Germany), and conducted according to the German Animal Protec-
tion Laws.
Data availability
All data that support the conclusions are available from the corre-
sponding author on request.
Expanded View for this article is available online.
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